The oral cavity is a unique clinical environment where traditional liquid medications are often washed away by saliva before they can exert a therapeutic effect. Our dental compounding practice focuses on overcoming this "washout" effect using advanced mucoadhesive technology.
A primary focus of our clinical interventions is the management of Oral Lichen Planus (OLP) and Burning Mouth Syndrome (BMS). For these conditions, we utilize PCCA MucoLox™, a specialized base that is clinically shown to adhere to the mucous membranes. This allows active ingredients, such as corticosteroids or nerve modulators, to remain in contact with the affected tissue for significantly longer periods than standard commercial mouthwashes. Additionally, we support dental practices in reducing "dental phobia" through the formulation of transdermal procedural anxiety creams and high-strength topical anesthetics (like the "Triple-Caine" gels). These allow for profound localized numbing and systemic relaxation without the need for full sedation, improving the patient experience and procedural outcomes for those with needle phobias or high sensitivity.
Common Formulations: * Mucoadhesive Rinses: Using MucoLox™ to treat OLP, Mucositis, and chronic aphthous ulcers.
- Topical Anesthetic Gels: High-concentration blends of Lidocaine, Tetracaine, and Prilocaine for painless injections.
- Dry Socket Suspensions: Specialized pastes containing Guaiacol and Eugenol to promote healing after extractions.
- Saliva Stimulants: Troches or sprays containing Pilocarpine for patients suffering from medication-induced Xerostomia (dry mouth).